# SynAct Pharma Reports No Q3 Revenue and Cash Runway Into Late 2027

> SynAct Pharma reported SEK 0 in third-quarter net sales and SEK 42,364 thousand in cash, with FDA feedback on its Phase 3 trial design expected by early 2027.

- Published: 2026-11-03T06:49:25+00:00
- Section: Earnings & Results
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-03/synact-pharma-q3-2026-interim-results
- Source: [TradingView](https://www.tradingview.com/news/modular_finance:cc84f639c172c:0-synact-pharma-publishes-q3-2026-interim-results/)

## Key takeaways

- SynAct Pharma reported net sales of SEK 0 for the third quarter of 2026 and operating expenses of SEK 30,087 thousand, down 15.0%.
- Cash and cash equivalents of SEK 42,364 thousand at period end give the company runway into the fourth quarter of 2027.
- SynAct expects FDA feedback on its Phase 3 trial design for resomelagon by the end of 2026 or early 2027.

SynAct Pharma reported net sales of SEK 0 for the third quarter of 2026 and operating expenses of SEK 30,087 thousand, down 15.0% from a year earlier, according to [TradingView](https://www.tradingview.com/news/modular_finance:cc84f639c172c:0-synact-pharma-publishes-q3-2026-interim-results/). The Swedish clinical-stage biotech ended the period with cash and cash equivalents of SEK 42,364 thousand.

## SynAct's Third-Quarter Loss and Cash Position

[SynAct Pharma](https://akta.pro/company-profiles/0002gmt/synact-pharma) is a Lund-based clinical-stage biotechnology company developing resomelagon, an oral selective melanocortin receptor agonist aimed at resolving inflammation rather than suppressing immunity, with rheumatoid arthritis, nephrotic syndrome and viral infections as target areas.

The group's loss after tax for the quarter was SEK 32,177 thousand, against SEK 35,690 thousand a year earlier. Earnings per share before and after dilution were -0.57 SEK, compared with -0.67 SEK. Cash flow from operating activities was SEK -18,714 thousand, cash flow from financing activities was SEK 46,241 thousand, and cash flow for the period was SEK 27,370 thousand.

For the first nine months of 2026, net sales were SEK 0 and operating expenses were SEK 85,201 thousand. The loss after tax for the nine months was SEK 79,696 thousand, and earnings per share were -1.44 SEK.

"Further analysis of data from the ADVANCE study with resomelagon in rheumatoid arthritis provides a clearer basis for designing our Phase 3 trial," said Jeppe Øvlesen, Chief Executive Officer of SynAct Pharma. "We expect feedback from the U.S. Food and Drug Administration by end of year or early 2027."

## SynAct's Funding and Patent Record

According to akta.pro [company records](https://akta.pro/company-data), SynAct completed a directed share issue in March 2026 of 2,883,725 shares at SEK 18.00, raising approximately SEK 51.9 million and extending cash runway into the third quarter of 2027. The same records list a July 2026 post-IPO debt round of $5.2 million led by Fenja Capital, and a June 2026 US patent for resomelagon securing composition exclusivity until 2044.

## ADVANCE Analysis and the Brazil Dengue Deal

On September 7, 2026, SynAct reported post hoc analysis of its phase 2b ADVANCE study showing resomelagon 40mg achieved a 79% ACR20 response versus 55% for placebo in patients with stable baseline inflammation, MarketScreener reported. DAS28-CRP declined 2.0 points for resomelagon versus 1.5 for placebo.

On October 27, 2026, SynAct signed a strategic agreement with Hipolabor Farmacêutica to jointly develop and commercialize resomelagon for dengue fever treatment in Brazil, Dagens industri reported. The company said in its interim report that FDA discussions on trial design were planned for the fourth quarter of 2026.

## FDA Feedback Timing for Resomelagon

SynAct said it expects FDA feedback on its Phase 3 trial design by the end of 2026 or early 2027. The company said its cash position provides runway into the fourth quarter of 2027 and beyond multiple potential value creating milestones.

## Companies in this story

- [SynAct Pharma company profile](https://akta.pro/company-profiles/0002gmt/synact-pharma) · website: https://www.synactpharma.com/sv

---
News for Agent · https://newsforagent.com/llms.txt